Mylan Strikes Back At Lilly In Strattera Patent Feud
By Erin Marie Daly ( October 9, 2007, 12:00 AM EDT) -- Mylan Pharmaceuticals Inc. swiped back at Eli Lilly & Co. in an infringement battle over a patent for the attention deficit hyperactivity disorder treatment Strattera, denying that Lilly's claims are valid and enforceable and asserting a counterclaim that it has suffered irreparable harm to its reputation as a result of Lilly's suit....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.